Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 16/20 | 0.41 |
| ▸ | BRD7 | Q9NPI1 | 7/20 | 0.41 |
| ▸ | TAF1 | P21675 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.41 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.41 |
| ▸ | ATAD2B | Q9ULI0 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 9/20 | 0.40 |
| ▸ | BRD2 | P25440 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25844167 | 0.89 | BRD9 (0.39) | BRD9BRD7TAF1TGFBR1BRPF1 | |
| SCHEMBL23799092 | 0.86 | BRD9 (0.45) | BRD9BRD7TAF1TGFBR1BRPF1 | |
| SCHEMBL33532796 | 0.85 | BRD9 (0.40) | BRD9BRD7TAF1TGFBR1BRPF1 | |
| SCHEMBL23783026 | 0.85 | BRD9 (0.44) | BRD9BRD7TAF1TGFBR1BRPF1 | |
| SCHEMBL25852361 | 0.84 | BRD9 (0.41) | BRD9BRD7TAF1TGFBR1BRPF1 | |
| SCHEMBL23798862 | 0.83 | BRD9 (0.43) | BRD9BRD7TAF1TGFBR1BRPF1 | |
| SCHEMBL25091959 | 0.83 | BRD9 (0.43) | BRD9BRD7TAF1TGFBR1BRPF1 | |
| SCHEMBL25852379 | 0.81 | BRD9 (0.39) | BRD9BRD7TAF1TGFBR1BRPF1 | |
| SCHEMBL25091096 | 0.81 | BRD9 (0.39) | BRD9BRD7TAF1TGFBR1BRPF1 | |
| SCHEMBL25091533 | 0.81 | BRD4 (0.46) | BRD9BRD7TAF1TGFBR1BRPF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | BRD9 1/4885BRD7 7/4885TAF1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.